202 related articles for article (PubMed ID: 2306797)
21. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen.
Zambetti M; Gianni L; Di Re F; Spatti G; Fontanelli R; Escobedo A; De Palo G; Bonadonna G
Am J Clin Oncol; 1990 Jun; 13(3):199-203. PubMed ID: 2161174
[TBL] [Abstract][Full Text] [Related]
22. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
[TBL] [Abstract][Full Text] [Related]
23. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
24. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
25. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of carboplatin and cisplatin in advanced ovarian cancer.
Segelov E; Stuart-Harris R; Bell D; Tattersall M; Hutton-Potts J; Friedlander M
Eur J Gynaecol Oncol; 1994; 15(4):277-82. PubMed ID: 7957335
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
29. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
Schmidinger M; Budinsky AC; Wenzel C; Piribauer M; Brix R; Kautzky M; Oder W; Locker GJ; Zielinski CC; Steger GG
Wien Klin Wochenschr; 2000 Jul; 112(14):617-23. PubMed ID: 11008323
[TBL] [Abstract][Full Text] [Related]
30. A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity.
Oriana S; Böhm S; Spatti G; Zunino F; Di Re F
Tumori; 1987 Aug; 73(4):337-40. PubMed ID: 3660470
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
32. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
33. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
[TBL] [Abstract][Full Text] [Related]
34. Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer.
Benedetti-Panici P; Greggi S; Scambia G; Salerno MG; Baiocchi G; Laurelli G; Menichella G; Pierelli L; Foddai ML; Serafini R
Eur J Cancer; 1995 Nov; 31A(12):1987-92. PubMed ID: 8562153
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
[TBL] [Abstract][Full Text] [Related]
36. Infusional cisplatin plus cyclophosphamide in advanced ovarian cancer.
Lokich J; Zipoli T; Green R
Cancer; 1986 Dec; 58(11):2389-92. PubMed ID: 3768834
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
[TBL] [Abstract][Full Text] [Related]
38. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
[TBL] [Abstract][Full Text] [Related]
39. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
Conte PF; Bruzzone M; Carnino F; Gadducci A; Algeri R; Bellini A; Boccardo F; Brunetti I; Catsafados E; Chiara S; Foglia G; Gallo L; Iskra L; Mammoliti S; Parodi G; Ragni N; Rosso R; Rugiati S; Rubagotti A
J Clin Oncol; 1996 Feb; 14(2):351-6. PubMed ID: 8636743
[TBL] [Abstract][Full Text] [Related]
40. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
